TY - JOUR
T1 - Report from the 2018 consensus conference on immunomodulating agents in thoracic transplantation
T2 - Access, formulations, generics, therapeutic drug monitoring, and special populations
AU - Cochrane, Adam B.
AU - Lyster, Haifa
AU - Lindenfeld, Jo Ann
AU - Doligalski, Christina
AU - Baran, David
AU - Yost, Colleen
AU - Shullo, Michael
AU - Schweiger, Martin
AU - Weill, David
AU - Stuckey, Linda
AU - Ivulich, Steven
AU - Scheel, Janet
AU - Peters, Lisa
AU - Colvin, Monica
AU - Dawson, Kyle
AU - Girgis, Reda
AU - Weeks, Phillip
AU - Tse, Tracy
AU - Russell, Stuart
AU - Flattery, Maureen
AU - Jennings, Doug
AU - Kittleson, Michelle
AU - Miller, Tara
AU - Khuu, Tam
AU - Claridge, Tamara
AU - Uber, Patricia
AU - Ford, Katrina
AU - Ensor, Christopher R.
AU - Simpson, Kathleen
AU - Dipchand, Anne
AU - Page, Robert L.
N1 - Funding Information:
J.L. is a consultant and principal investigator for and reports a research grant from Novartis. D.B. is a principal investigator for and reports a research grant from Astellas. K.F. is on the advisory board for Novartis. C.R.E. reports research grants from Amgen, CSL Behring, and United Therapeutics and is on the advisory board for Baxalta. M. J. B is a consultant for Novartis, Biotest, and Abbott. The remaining authors have no conflicts of interest to disclose.
Publisher Copyright:
© 2020 International Society for Heart and Lung Transplantation
PY - 2020/10
Y1 - 2020/10
N2 - In 2009, the International Society for Heart and Lung Transplantation recognized the importance and challenges surrounding generic drug immunosuppression. As experience with generics has expanded and comfort has increased, substantial issues have arisen since that time with other aspects of immunomodulation that have not been addressed, such as access to medicines, alternative immunosuppression formulations, additional generics, implications on therapeutic drug monitoring, and implications for special populations such as pediatrics and older adults. The aim of this consensus document is to address critically each of these concerns, expand on the challenges and barriers, and provide therapeutic considerations for practitioners who manage patients who need to undergo or have undergone cardiothoracic transplantation.
AB - In 2009, the International Society for Heart and Lung Transplantation recognized the importance and challenges surrounding generic drug immunosuppression. As experience with generics has expanded and comfort has increased, substantial issues have arisen since that time with other aspects of immunomodulation that have not been addressed, such as access to medicines, alternative immunosuppression formulations, additional generics, implications on therapeutic drug monitoring, and implications for special populations such as pediatrics and older adults. The aim of this consensus document is to address critically each of these concerns, expand on the challenges and barriers, and provide therapeutic considerations for practitioners who manage patients who need to undergo or have undergone cardiothoracic transplantation.
KW - generic immunosuppression
KW - heart transplantation
KW - immunosuppression
KW - lung transplantation
KW - pediatric transplantation
UR - http://www.scopus.com/inward/record.url?scp=85090057022&partnerID=8YFLogxK
U2 - 10.1016/j.healun.2020.06.024
DO - 10.1016/j.healun.2020.06.024
M3 - Editorial
C2 - 32883559
AN - SCOPUS:85090057022
VL - 39
SP - 1050
EP - 1069
JO - Journal of Heart and Lung Transplantation
JF - Journal of Heart and Lung Transplantation
SN - 1053-2498
IS - 10
ER -